Publications by authors named "Isabella E P de Azevedo"
Preliminary Study for New Markers of Early Tubuloglomerular Injury and Renal Inflammation in Patients with Visceral Leishmaniasis Receiving Liposomal Amphotericin B Treatment.
Am J Trop Med Hyg
April 2022
Article Synopsis
- Visceral leishmaniasis patients treated with liposomal amphotericin B (L-AMB) may experience nephrotoxicity, prompting a study to assess renal damage through specific biomarkers.
- A prospective study with 17 patients analyzed various kidney function tests and biomarkers before and during L-AMB treatment.
- Findings indicated that while traditional kidney function metrics remained stable, specific inflammatory and urinary biomarkers increased, particularly in patients who developed acute kidney injury, highlighting the need for close monitoring during treatment.
Antiparasitic effect of (-)-α-bisabolol against Trypanosoma cruzi Y strain forms.
Diagn Microbiol Infect Dis
November 2019
Chagas disease is caused by Trypanosoma cruzi and affects about 7 million people worldwide. Benznidazole and nifurtimox have low efficacy and high toxicity. The present study was designed to identify the trypanocidal effect of (-)-α-Bisabolol (BIS) and investigate its mechanism.
View Article and Find Full Text PDFAcute Kidney Injury (AKI) is associated with high morbidity and mortality. Ischemia and reperfusion (I/R) are events that lead to AKI through hypoxia, reactive oxygen species (ROS) production, oxidative stress and apoptosis. We aimed to evaluate the mechanism of nephroprotection mediated by Bisabolol in human tubular kidney cells after injury by I/R in vitro.
View Article and Find Full Text PDFObjective: To evaluate the usefulness of early acute kidney injury (AKI) biomarkers in clinical management of visceral leishmaniasis.
Methods: Prospective study with 50 hospitalised VL patients. AKI biomarkers, that is, serum and urinary neutrophil gelatinase-associated lipocalin (sNGAL, uNGAL, respectively), urinary kidney injury molecule-1 (uKIM-1) and urinary monocyte chemotactic protein-1 (uMCP-1), were quantified by immunoassay (ELISA).